Search results
Results From The WOW.Com Content Network
Since November 2023, CRISPR Therapeutics has been earning approvals for Casgevy, a gene-editing medicine, in various countries and regions. This new coverage could also make it easier once CRISPR ...
Dylan Lewis: We're talking three stocks down bad. Motley Fool Money starts down. Motley Fool Money starts down. I'm Dylan Lewis, I'm joined over the airwaves by Motley Fool analyst David Meier.
The biotech industry has lagged the broader market so far in 2024. Despite moving in opposite directions in 2024, CRISPR Therapeutics and Exelixis have strong prospects. CRISPR Therapeutics is a ...
The biotech stock rocketed higher last spring, but the gains didn't last long. Since reaching a peak last May, Moderna stock has tumbled by about 79%, and investors are starting to wonder if it ...
To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this year: Vertex Pharmaceuticals (NASDAQ: VRTX) and Moderna (NASDAQ: MRNA).
Biotech and health care stocks looked like they needed a transfusion of market confidence Monday, as for the second session in a row, their performance was anemic. Investors are trying to ...
After the company revealed the pricing details of its common stock offering, shares of Moleculin Biotech Inc (NASDAQ:MBRX) tanked nearly 26% in Friday's trading session.Moleculin announced this ...
Here is why now is as good a time as any to "buy low" when it comes to this stock. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy ...